Caloric Restriction Is the Most Reproducible Intervention for Extending Both Lifespan and Healthspan Across Model Organisms — From Yeast to Rhesus Monkeys — and the CALERIE Trial Demonstrated That 25% CR in Healthy Humans Over Two Years Improves Cardiovascular Risk, Reduces Inflammation, and Slows Epigenetic Aging: Here Is the Complete Molecular Biology and the Practical Implementation
Updated: June 2026caloric restriction longevity · calorie restriction longevity · caloric restriction life extension · calorie restriction life extension · caloric restriction aging · calorie restriction aging · does caloric restriction extend lifespan · caloric restriction lifespan · calorie restriction lifespan · CALERIE trial · CALERIE study · CALERIE trial results · Ravussin CALERIE · caloric restriction humans · 25 percent caloric restriction · caloric restriction human trial · caloric restriction RCT · caloric restriction benefits · caloric restriction health effects · caloric restriction metabolism · caloric restriction inflammation · caloric restriction epigenetic aging · caloric restriction epigenetic clock · caloric restriction Horvath clock · caloric restriction telomere · caloric restriction NIA monkey study · NIA rhesus monkey caloric restriction · NIA primate caloric restriction · WNPRC monkey caloric restriction · Wisconsin rhesus monkey study · rhesus monkey CR study · primate caloric restriction lifespan · Colman 2009 Science CR monkeys · Colman 2014 Nature CR monkeys · Mattison 2012 Nature CR NIA · CR monkey comparison NIA WNPRC · mTOR caloric restriction · mTOR inhibition CR · caloric restriction mTOR · AMPK caloric restriction · AMPK activation CR · AMPK energy sensing · AMPK AMP ATP ratio · caloric restriction SIRT1 · SIRT1 CR · caloric restriction sirtuins · CR NAD+ · caloric restriction NAD · caloric restriction FOXO · FOXO transcription factor · FOXO3 longevity · FOXO longevity gene · IIS pathway · insulin IGF-1 signaling pathway · IIS longevity · insulin signaling aging · IGF-1 aging · IGF-1 longevity · daf-2 pathway · C elegans longevity · Kenyon 1993 · Kenyon longevity IIS · reduced IGF-1 longevity · caloric restriction IGF-1 · CR IGF-1 reduction · caloric restriction glucose · caloric restriction insulin · caloric restriction insulin sensitivity · caloric restriction diabetes · caloric restriction blood pressure · caloric restriction cardiovascular · caloric restriction LDL · caloric restriction cholesterol · caloric restriction triglycerides · caloric restriction CRP · caloric restriction inflammation markers · caloric restriction thyroid · caloric restriction T3 · caloric restriction body temperature · caloric restriction energy expenditure · caloric restriction adaptive thermogenesis · caloric restriction muscle loss · caloric restriction lean mass · caloric restriction protein · caloric restriction protein intake · intermittent fasting vs caloric restriction · IF vs CR · time restricted eating longevity · 16:8 fasting longevity · caloric restriction alternative · caloric restriction mimetic · rapamycin CR mimetic · metformin CR mimetic · resveratrol CR mimetic · Mediterranean diet longevity · Mediterranean diet CR · Mediterranean diet caloric restriction · Blue Zone diet · Blue Zone longevity · Okinawa diet caloric restriction · Okinawa hara hachi bu · caloric restriction quality of life · caloric restriction hunger · caloric restriction adherence · how to do caloric restriction · caloric restriction protocol · CR how much · caloric restriction 20 percent · caloric restriction 25 percent · caloric restriction 30 percent
Caloric restriction (CR) — reducing caloric intake by 20–40% below ad libitum levels while maintaining adequate nutrition — is the intervention with the longest and most reproducible track record for extending lifespan across model organisms. It extends lifespan in yeast, nematodes (C. elegans), fruit flies (Drosophila), multiple rodent strains, and — in the most relevant recent data — rhesus monkeys. The molecular mechanisms through which CR extends lifespan are now partially understood: they converge on three nutrient-sensing pathways (mTOR, AMPK, and the insulin/IGF-1 signaling axis) and downstream effectors including sirtuins and FOXO transcription factors — many of which are also the targets of pharmacological longevity interventions like rapamycin and metformin.
The translation to humans has been the central question. The CALERIE (Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy) trial — a multi-center RCT funded by the NIH and led by Eric Ravussin, Leanne Redman, and colleagues — provided the most rigorous human CR data available: 218 healthy, non-obese adults randomized to 25% caloric restriction or ad libitum eating for two years. The CALERIE results confirmed that sustained CR in humans is safe, produces meaningful improvements in cardiometabolic risk factors and inflammatory markers, and — in a post-hoc epigenetic analysis — appears to slow epigenetic aging as measured by DNA methylation clocks.
CALERIE
the human CR trial — CALERIE Phase 2 (Ravussin et al., multiple publications 2015–2022); N=218 healthy non-obese adults (BMI 22–27.9, age 21–50); design: randomized 2:1 to 25% CR or ad libitum eating; duration: 24 months; achieved CR: participants achieved approximately 11.9% CR on average (target was 25% — illustrating the difficulty of sustained CR in free-living conditions); CALERIE cardiovascular findings (Kraus et al. 2019, Lancet Diabetes Endocrinology): significant reductions in: LDL cholesterol; blood pressure; insulin resistance (HOMA-IR); triglycerides; significant increase in HDL; CALERIE inflammation findings: reduced hsCRP, IL-6, and TNF-α — markers of chronic systemic inflammation; CALERIE quality of life: contrary to expectation, CR participants reported improved mood, improved sleep quality, and improved sexual drive at 2 years — consistent with rodent studies showing improved quality of life markers with CR; CALERIE metabolic adaptation: CR reduced resting metabolic rate and body temperature — classic CR responses also seen in long-lived animals; CALERIE epigenetic clock analysis (Waziry et al. 2023, Nature Aging): post-hoc DNA methylation analysis using the DunedinPACE epigenetic aging clock; result: CR significantly slowed the pace of biological aging — approximately 2–3% slower aging pace in the CR group; this is the first human evidence that CR slows epigenetic aging in vivo; context: this was a secondary analysis of a trial not powered for epigenetic outcomes; the effect size was modest; but it is consistent with the direction predicted from model organism data
Primate Data
the monkey studies — two independent 20%–30% CR studies in rhesus monkeys (the most genetically and physiologically relevant pre-clinical model) reached different conclusions, generating significant scientific debate before a reconciliation analysis: WNPRC study (University of Wisconsin): Colman et al. 2009 (Science); 2014 follow-up: 20% CR started in young adult monkeys; result: significant reduction in age-related disease incidence (diabetes, cancer, cardiovascular disease, brain atrophy) and significant lifespan extension in CR monkeys; this was the landmark positive result; NIA study (National Institute on Aging): Mattison et al. 2012 (Nature): similar CR protocol; result: NO significant lifespan extension; the apparent contradiction: Colman vs Mattison raised questions about whether CR truly extends primate lifespan; the reconciliation (Mattison et al. 2017, Nature Communications): the difference was in the control groups; the NIA controls ate a less calorie-dense, healthier diet than the WNPRC controls (the NIA controlled diet had lower sugar and less processed ingredients); NIA control monkeys were already partially CR'd relative to typical Western-style diet → less room for additional CR benefit; the WNPRC controls ate ad libitum with higher-sugar diet → larger gap between CR and control → larger CR effect; conclusion: CR extends rhesus lifespan when the comparison is against an unhealthy ad libitum diet (relevant to Western humans); the benefit narrows when the control diet is already healthier (relevant to health-conscious individuals)
mTOR + AMPK
the molecular switches — caloric restriction activates a cascade of molecular events through three primary nutrient-sensing axes: (1) mTOR INHIBITION: mTORC1 (mechanistic target of rapamycin complex 1) is the master anabolic sensor — activated by amino acids and insulin, it promotes protein synthesis, cell growth, and suppresses autophagy; caloric restriction → reduced amino acid availability + reduced insulin → reduced mTORC1 activity → increased autophagy (cellular recycling of damaged proteins and organelles) → improved cellular quality control; this is the same pathway inhibited by rapamycin, which is why rapamycin and CR produce overlapping benefits and have additive effects when combined; (2) AMPK ACTIVATION: AMPK (AMP-activated protein kinase) is the cellular energy sensor — it is activated when the AMP:ATP ratio rises (low energy state); caloric restriction → lower cellular energy → higher AMP:ATP → AMPK activation → activates mitochondrial biogenesis (PGC-1α phosphorylation), fatty acid oxidation, glucose uptake, autophagy; simultaneously inhibits mTORC1 (through Raptor phosphorylation and TSC1/2 activation); metformin mimics this AMPK activation by inhibiting mitochondrial complex I; (3) IIS (INSULIN/IGF-1 SIGNALING) PATHWAY: caloric restriction → reduced insulin and IGF-1 secretion → reduced PI3K-AKT-mTOR signaling → nuclear translocation of FOXO transcription factors → upregulation of stress resistance, autophagy, and antioxidant defense genes; the IIS pathway is the primary longevity pathway identified in C. elegans (daf-2 mutants, lacking insulin receptor homolog, live 2× longer — Kenyon 1993); FOXO3 variants are the most replicated human longevity gene polymorphism, with FOXO3 "longevity alleles" consistently enriched in centenarians across multiple cohort studies
CR vs Exercise
comparison and combination — the comparison between caloric restriction and exercise is often framed as competitive, but they activate overlapping but distinct pathways: OVERLAP: both CR and exercise activate AMPK; both increase NAD+:NADH ratio; both improve insulin sensitivity; both reduce inflammatory markers; both improve cardiovascular risk factors; the longevity effects are partially additive; DIVERGENCES: exercise INCREASES lean mass (muscle) while CR tends to reduce it; CR typically reduces body temperature and metabolic rate; exercise maintains or increases metabolic rate; the muscle mass difference is clinically significant — lean mass preservation with age is independently protective against mortality and functional decline; CR without adequate protein + exercise can produce sarcopenia (muscle loss — the same concern as with GLP-1-induced weight loss); exercise cannot reproduce all CR benefits: the CR reduction in IGF-1 may require actual caloric restriction, not just exercise-induced negative energy balance; the CALERIE CR participants did not exercise systematically; COMBINATION PROTOCOL: the most evidence-supported longevity intervention combines mild CR (10–20%, not the harsh 25% of CALERIE), high protein intake (1.2–1.6g/kg/day to protect lean mass), and resistance training + Zone 2 exercise; this combination activates AMPK, mTOR cycling (inhibited at rest, activated post-training for muscle), sirtuin activity, and cardiovascular adaptation simultaneously; whole food Mediterranean-style eating pattern naturally reduces caloric density (high fiber, high water content, lower energy density foods) → passive CR of 10–15% vs Western diet without deliberate caloric counting
Ready to build the full protocol?
The Longevity Stack ranks 20+ compounds by evidence tier — the full biomarker panel, VO2 max protocol, sleep science, hormone chapter, and three budget-level stacks, built from the same research on this page.
Get the Longevity Stack → $19
CR Pathways vs Pharmacological Mimetics
| Intervention | Primary Target | mTOR | AMPK | SIRT1 | FOXO | Lifespan Data |
|---|
| Caloric Restriction | All nutrient sensors | ↓ (inhibits) | ↑ (activates) | ↑ (NAD+ increase) | ↑ (nuclear) | Strong: multiple organisms; +20% in rodents |
| Rapamycin | mTORC1 | ↓↓ (direct) | No effect | Indirect ↑ | Indirect ↑ | Harrison 2009: +14–28% in ITP mice |
| Metformin | Complex I → AMPK | ↓ (indirect) | ↑↑ (direct) | Indirect ↑ | Indirect ↑ | TAME trial (human longevity): pending |
| Exercise | Energy deficit → AMPK | ↑ post-exercise | ↑↑ (during) | ↑ (NAD+) | ↑ (stress) | VO2 max: 5× mortality reduction (Mandsager 2018) |
| Intermittent Fasting | Periodic nutrient absence | ↓ (fasting window) | ↑ (fasting window) | ↑ (NAD+ ratio) | ↑ | Rodent: strong; Human: limited longevity data |
| Mediterranean Diet | Passive CR + polyphenols | Modest ↓ | Modest ↑ | Indirect ↑ | Indirect ↑ | PREDIMED: −30% MACE; observational lifespan data |
Practical CR Implementation — The Evidence-Based Protocol
What CR does NOT mean: starvation; extreme restriction; eliminating protein; nutrient deficiency; permanent hunger; the CALERIE participants with best adherence ate a varied, nutritionally complete diet — they reduced caloric density (eating more vegetables, lean protein, and less processed food) rather than simply eating less of everything; crash dieting without nutrition adequacy is physiologically harmful and not the CR studied in longevity research.
Target CR level for practical implementation: the CALERIE target was 25%; participants achieved ~12%; most longevity researchers now recommend 10–20% below your typical intake as a sustainable target; this can be achieved through: (a) TIME-RESTRICTED EATING (16:8): confining eating to an 8-hour window naturally reduces caloric intake by 10–20% in most people without deliberate calorie counting; (b) CALORIC DENSITY REDUCTION: replace energy-dense foods (refined grains, processed snacks, sugar-sweetened beverages) with low-caloric-density whole foods (vegetables, legumes, lean protein, berries) — this passively reduces total intake while maintaining volume; the Mediterranean dietary pattern achieves this naturally; (c) PROTEIN-ADEQUATE CR: maintain 1.2–1.6g protein/kg body weight to preserve lean mass; CR without adequate protein produces muscle loss — counterproductive for longevity.
Monitoring markers of CR benefit: fasting insulin (target <5 μIU/mL on moderate CR); IGF-1 (moderate reduction is expected with CR — low IGF-1 is a longevity marker; very low IGF-1 may reduce lean mass); hsCRP (target <1 mg/L — anti-inflammatory effect of CR); fasting glucose; body temperature (slight reduction is expected on effective CR — thermometer self-tracking); epigenetic clocks (GrimAge, DunedinPACE available commercially at $300–600 — baseline + 12 months provides the most meaningful data for tracking whether CR is producing biological age deceleration).
CGM Metabolic Tracking →
Berberine (AMPK) →
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.